Latest Distribution Agreements News

OMG Group delivered a near 50% jump in FY26 net sales, expanding its product range nationally and breaking into international markets with new distribution agreements.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

FBR Limited has partnered with Industrial Robotics LLC to distribute and support its Mantis™ welding robots across the United States and Canada, targeting key southern states and expanding its footprint without increasing headcount.

Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

First Graphene has signed an MOU with Sixth Element to distribute its PureGRAPH® CEM additive across China, with potential for local manufacturing via a joint venture once sales milestones are met.

Associate Global Partners has partnered with US investment manager ARK to bring the ARK Venture Fund to Australian wholesale investors, expanding AGP's access to high-growth private companies focused on technological disruption.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Sprintex Limited has locked in underwriting agreements covering 8.7 million unexercised options, potentially raising up to A$870,000. The company also agreed to extend a A$1.85 million convertible note maturity by one year, pending shareholder approval.